正在进行的开放标签延伸阶段将进一步提供有关治疗的长期疗效和安全性的信息。 Espay AJ, Stocchi F, Pahwa R, Albanese A, Ellenbogen A, Ferreira JJ, Giladi N, Gurevich T, Hassin-Baer S, Hernandez-Vara J, Isaacson SH,...
24 hours/day subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD) – in comparison to oral immediate-release (IR) LD/CD in Parkinson's disease (PD) patients with motor fluctuations, met its primary endpoint and the first four secondary endpoints, ...
ND0612Parkinson's diseasePharmacokineticsND0612 is a continuous, subcutaneous levodopa/carbidopa delivery system under development for patients with Parkinson's disease (PD) and motor fluctuations.#This was a randomized, placebo-controlled, double-blind, 2-period study evaluating the safety and ...
近日,以色列的生物制药公司NeuroDerm宣布开始为名为“iNDiGO”的临床III期试验进行患者注册。这项临床试验是为了检验该公司名为ND0612L的左旋多巴/卡比多巴(Levodopa/Carbidopa) 配方在治疗中度帕金森氏症(Parkinson's Disease)方面的疗效。ND0612L是目前唯一一种液态的左旋多巴/卡比多巴配方,这种配方能够持续稳定地通...
Nir Giladi a b cTanya Gurevich a b cRuth Djaldetti b dLiat Adar eRyan Case eShelly Leibman-Barak eNissim Sasson eYoseph Caraco f
Objective: To evaluate the pharmacokinetic–pharmacodynamic relationships between levodopa plasma exposure and motor treatment response in patients with Parkinson's disease (PD) treated with ND0612 and adjunct oral PD medication.Background: ND0612 is an investigational subcutaneous delivery system providing ...
(SC) levodopa/carbidopa (LD/CD) infusion with ND0612 versus levodopa derived from oral immediate-release LD/CD (IR-LD/CD) tablets in healthy volunteers.Background: ND0612 is in development as the first continuous SC LD/CD delivery system for patients with Parkinson's disease (PD) ...